NAVB vs. SCHG
Compare and contrast key facts about Navidea Biopharmaceuticals, Inc. (NAVB) and Schwab U.S. Large-Cap Growth ETF (SCHG).
SCHG is a passively managed fund by Charles Schwab that tracks the performance of the Dow Jones U.S. Large-Cap Growth Total Stock Market Total Return Index. It was launched on Dec 11, 2009.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NAVB or SCHG.
Correlation
The correlation between NAVB and SCHG is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NAVB vs. SCHG - Performance Comparison
Key characteristics
NAVB:
-0.09
SCHG:
1.64
NAVB:
8.42
SCHG:
2.19
NAVB:
3.12
SCHG:
1.30
NAVB:
-0.98
SCHG:
2.37
NAVB:
-1.14
SCHG:
8.98
NAVB:
85.97%
SCHG:
3.27%
NAVB:
1,069.72%
SCHG:
17.91%
NAVB:
-100.00%
SCHG:
-34.59%
NAVB:
-100.00%
SCHG:
-1.27%
Returns By Period
In the year-to-date period, NAVB achieves a 700.00% return, which is significantly higher than SCHG's 3.09% return. Over the past 10 years, NAVB has underperformed SCHG with an annualized return of -65.49%, while SCHG has yielded a comparatively higher 16.44% annualized return.
NAVB
700.00%
700.00%
-20.00%
-98.33%
-76.57%
-65.49%
SCHG
3.09%
0.91%
13.95%
31.06%
18.74%
16.44%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NAVB vs. SCHG — Risk-Adjusted Performance Rank
NAVB
SCHG
NAVB vs. SCHG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Navidea Biopharmaceuticals, Inc. (NAVB) and Schwab U.S. Large-Cap Growth ETF (SCHG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NAVB vs. SCHG - Dividend Comparison
NAVB has not paid dividends to shareholders, while SCHG's dividend yield for the trailing twelve months is around 0.38%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NAVB Navidea Biopharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SCHG Schwab U.S. Large-Cap Growth ETF | 0.38% | 0.40% | 0.46% | 0.55% | 0.42% | 0.52% | 0.82% | 1.27% | 1.01% | 1.04% | 1.22% | 1.09% |
Drawdowns
NAVB vs. SCHG - Drawdown Comparison
The maximum NAVB drawdown since its inception was -100.00%, which is greater than SCHG's maximum drawdown of -34.59%. Use the drawdown chart below to compare losses from any high point for NAVB and SCHG. For additional features, visit the drawdowns tool.
Volatility
NAVB vs. SCHG - Volatility Comparison
Navidea Biopharmaceuticals, Inc. (NAVB) has a higher volatility of 351.89% compared to Schwab U.S. Large-Cap Growth ETF (SCHG) at 4.79%. This indicates that NAVB's price experiences larger fluctuations and is considered to be riskier than SCHG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.